Oncimmune Holdings PLC Data presented at the 11th Annual ILCA
18 September 2017 - 4:01PM
RNS Non-Regulatory
TIDMONC
Oncimmune Holdings PLC
18 September 2017
18 September 2017
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Data relating to the development of Oncimmune's
EarlyCDT(R)-Liver panel presented at the 11(th) International Liver
Cancer Association
Nottingham, UK - 18 September 2017: Oncimmune Holdings plc (AIM:
ONC.L), a leading early cancer detection company developing and
commercialising its proprietary EarlyCDT(R) platform technology,
today announces that data relating to the development of its
EarlyCDT(R)-Liver panel was presented at the 11(th) Annual
International Liver Cancer Association (ILCA), which took place
from Friday 15(th) to Sunday 17(th) September 2017, in Seoul, South
Korea.
A presentation called "Autoantibodies as additive biomarkers to
AFP for the detection of HCC" showed that a panel of 10
autoantibodies could detect hepatocellular carcinoma (HCC) with
high sensitivity and specificity. The test was also able to
distinguish HCC from patients with chronic liver disease regardless
of stage or tumour size.
These results provided the data for Oncimmune to develop its
next test to launch - EarlyCDT-Liver - which is in its final stages
of autoantibody panel selection and validation. The test is
expected to be launched in the first half of 2018 and will
significantly improve the performance of the current existing
diagnostic test alpha fetoprotein (AFP), which has come under
scrutiny as the levels can be raised in many patients who have
liver disease but not HCC.
Geoffrey Hamilton-Fairley, Chief Executive Officer, commented:
"The detection of hepatocellular carcinoma at an early stage is
crucial for a positive outcome. It is an especially big problem in
Asia, and in Asian populations in Europe and America, where the
incidence is many times that in the non-Asian populations due to
Hepatitis B and C. Despite its low performance, many millions of
AFP tests are carried out each year using a simple 96 well ELISA
test similar to the EarlyCDT tests. The majority of hospitals
worldwide have access to a 96 well ELISA reader and thus we believe
that this better performing test should be welcomed throughout
affected communities.
Poster details
Title: Autoantibodies as additive biomarkers to AFP for the detection of HCC
Number: P-083
Authors: Christopher Welberry, William Irving, Andrea Murray, Caroline Chapman
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited
Phil Walker, Giles Balleny, Hugh Kingsmill Moore
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708
About Oncimmune
Oncimmune is a leading early cancer detection company developing
and commercialising its proprietary EarlyCDT(R) platform
technology. Oncimmune has pioneered the development of autoantibody
tests that can detect cancer up to four years earlier than other
methods and can be applied to a very wide range of solid tumour
types. The Company's first product, EarlyCDT(R)-Lung, was launched
in 2012, as a CLIA test in the USA and since then over 150,000
commercial tests have been sold. EarlyCDT(R)-Lung is available
through physicians in the US and also privately in the UK and other
regions. EarlyCDT(R)-Lung is being used in the largest ever
randomised trial for the early detection of lung cancer using
biomarkers. The NHS Scotland ECLS study of over 12,000 high-risk
smokers is now fully recruited and in the final follow up stage.
EarlyCDT(R) tests for liver and ovarian cancer are in
development.
Oncimmune, headquartered in Nottingham, United Kingdom with
testing facilities in the US, joined AIM in May 2016 under the
ticker ONC.L. For more information visit www.oncimmune.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGGUWWBUPMGCA
(END) Dow Jones Newswires
September 18, 2017 02:01 ET (06:01 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024